S100B overexpressing mutant mice exhibit prolonged behavioural and biochemical responses towards repeated intermittent binge treatments with MDMA

International Journal of Neuropsychopharmacology

Volumn 12, Issue 2, 2009, Pages 201-215

  Kindlundh Högberg, Anna M S ^a   Zhang, Xiaoqun ^a   Svenningsson, Per ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

5 HT1B receptor; Ecstasy; Psychostimulant; Serotonin

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; DOPAMINE TRANSPORTER; GUANINE NUCLEOTIDE BINDING PROTEIN; MESSENGER RNA; PROTEIN S100B; SEROTONIN 1B RECEPTOR; SEROTONIN TRANSPORTER; SODIUM CHLORIDE; GUANOSINE 5' O (3 THIOTRIPHOSPHATE); NERVE GROWTH FACTOR; PROTEIN S 100; PSYCHEDELIC AGENT; S 100 CALCIUM BINDING PROTEIN BETA SUBUNIT; S-100 CALCIUM-BINDING PROTEIN BETA SUBUNIT;

ADAPTATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BIOCHEMISTRY; COMPARATIVE STUDY; COMPREHENSION; CONTROLLED STUDY; CORPUS STRIATUM; DENSITY; DOWN REGULATION; EXPLORATORY BEHAVIOR; GENE EXPRESSION; GENETIC DIFFERENCE; GENOTYPE; GLOBUS PALLIDUS; MALE; MAZE TEST; MODULATION; MOUSE; MUTANT; NERVE CELL PLASTICITY; NONHUMAN; OPEN FIELD BEHAVIOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; REARING; SEROTONINERGIC SYSTEM; SUBSTANTIA NIGRA; UPREGULATION; WILD TYPE; ANALYSIS OF VARIANCE; ANIMAL; ANIMAL BEHAVIOR; AUTORADIOGRAPHY; BRAIN; BRAIN LEVEL; C57BL MOUSE; DRUG ADMINISTRATION; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; LOCOMOTION; METABOLISM; METHODOLOGY; MOUSE MUTANT; PHYSIOLOGY; PROTEIN BINDING; TIME;

ANALYSIS OF VARIANCE; ANIMALS; AUTORADIOGRAPHY; BEHAVIOR, ANIMAL; BRAIN; BRAIN CHEMISTRY; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DRUG ADMINISTRATION SCHEDULE; EXPLORATORY BEHAVIOR; GENE EXPRESSION; GENE EXPRESSION REGULATION; GUANOSINE 5'-O-(3-THIOTRIPHOSPHATE); HALLUCINOGENS; LOCOMOTION; MAZE LEARNING; MICE; MICE, INBRED C57BL; MICE, MUTANT STRAINS; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; NERVE GROWTH FACTORS; PROTEIN BINDING; RECEPTOR, SEROTONIN, 5-HT1B; RNA, MESSENGER; S100 PROTEINS; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; TIME FACTORS;

EID: 67049098280     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145708009437     Document Type: Article

References (63)

1. Arolt V, Peters M, Erfurth A, Wiesmann M, Missler U, Rudolf S, Kirchner H, Rothermundt M (2003). S100B and response to treatment in major depression: a pilot study. European Neuropsychopharmacology 13, 235-239.
2. Azmitia EC, Dolan K, Whitaker-Azmitia PM (1990). S-100B but not NGF, EGF, insulin or calmodulin is a CNS serotonergic growth factor. Brain Research 516, 354-356.
3. Azmitia EC, Rubinstein VJ, Strafaci JA, Rios JC, Whitaker-Azmitia PM (1995). 5-HT1A agonist and dexamethasone reversal of para-chloroamphetamine induced loss of MAP-2 and synaptophysin immunoreactivity in adult rat brain. Brain Research 677, 181-192.
4. Bengel D, Murphy DL, Andrews AM, Wichems CH, Feltner D, Heils A, Mossner R, Westphal H, Lesch KP (1998). Altered brain serotonin homeostasis and locomotor insensitivity to 3,4-methylenedioxymethamphetamine ('Ecstasy') in serotonin transporter-deficient mice. Molecular Pharmacology 53, 649-655.
5. Berridge KC, Robinson TE (1998). What is the role of dopamine in reward: hedonic impact, reward learning, or incentive salience? Brain Research. Brain Research Reviews 28, 309-369.
6. Boschert U, Amara DA, Segu L, Hen R (1994). The mouse 5-hydroxytryptamine1B receptor is localized predominantly on axon terminals. Neuroscience 58, 167-182.
7. Check E (2004). Psychedelic drugs: the ups and downs of ecstasy. Nature 429, 126-128.
8. Colado MI Camarero J Mechan AO Sanchez V Esteban B Elliott JM Green AR (2001). A study of the mechanisms involved in the neurotoxic action of 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy') on dopamine neurones in mouse brain. British Journal of Pharmacology 134, 1711-1723.
9. Cole JC, Sumnall HR (2003). Altered states: the clinical effects of Ecstasy. Pharmacology & Therapeutics 98, 35-58.
10. Di Chiara G (1999). Drug addiction as dopamine-dependent associative learning disorder. European Journal of Pharmacology 375, 13-30.
11. Eriksen JL, Gillespie R, Druse MJ (2002). Effects of ethanol and 5-HT1A agonists on astroglial S100B. Brain Research. Developmental Brain Research 139, 97-105.
12. Eriksen JL, Gillespie RA, Druse MJ (2000). Effects of in utero ethanol exposure and maternal treatment with a 5-HT(1A) agonist on S100B-containing glial cells. Brain Research. Developmental Brain Research 121, 133-143.
13. Everitt BJ, Parkinson JA, Olmstead MC, Arroyo M, Robledo P, Robbins TW (1999). Associative processes in addiction and reward. The role of amygdala-ventral striatal subsystems. Annals of the New York Academy of Sciences 877, 412-438.
14. Gerfen CR, Engber TM, Mahan LC, Susel Z, Chase TN, Monsma Jr. F, Sibley DR (1990). D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science 250, 1429-1432.
15. Green AR, Mechan AO, Elliott JM, O'Shea E, Colado MI (2003). The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy'). Pharmacological Reviews 55, 463-508.
16. Griffin WS, Sheng JG, McKenzie JE, Royston MC, Gentleman SM, Brumback RA, Cork LC, Del Bigio MR, Roberts GW, Mrak RE (1998). Life-long overexpression of S100beta in Down's syndrome: implications for Alzheimer pathogenesis. Neurobiology of Aging 19, 401-405.
17. Griffin WS, Stanley LC, Ling C, White L, MacLeod V, Perrot LJ, White 3rd CL, Araoz C (1989). Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease. Proceedings of the National Academy of Sciences USA 86, 7611-7615.
18. Gudelsky GA, Nash JF (1996). Carrier-mediated release of serotonin by 3,4-methylenedioxymethamphetamine: implications for serotonin-dopamine interactions. Journal of Neurochemistry 66, 243-249.
19. Han DD, Gu HH (2006). Comparison of the monoamine transporters from human and mouse in their sensitivities to psychostimulant drugs. BMC Pharmacol 6, 6.
20. Inazu M, Takeda H, Ikoshi H, Sugisawa M, Uchida Y, Matsumiya T (2001). Pharmacological characterization and visualization of the glial serotonin transporter. Neurochemistry International 39, 39-49.
21. Jacobs BL, Fornal CA (1999). Activity of serotonergic neurons in behaving animals. Neuropsychopharmacology 21, 9S-15S.
22. Kalivas PW, Nakamura M (1999). Neural systems for behavioral activation and reward. Current Opinion in Neurobiology 9, 223-227.
23. Kalivas PW, Sorg BA, Hooks MS (1993). The pharmacology and neural circuitry of sensitization to psychostimulants. Behavioral Pharmacology 4, 315-334.
24. Kindlundh-Högberg AMS, Svenningsson P, Schiöth HB (2006). Quantitative mapping shows that serotonin rather than dopamine receptor mRNA expressions are affected after repeated intermittent administration of MDMA in rat brain. Neuropharmacology 51, 838-847.
25. Koob GF, Le Moal M (2001). Drug addiction, dysregulation of reward, and allostasis. Neuropsychopharmacology 24, 97-129.
26. Krause JE, Chirgwin JM, Carter MS, Xu ZS, Hershey AD (1987). Three rat preprotachykinin mRNAs encode the neuropeptides substance P and neurokinin A. Proceedings of the National Academy of Sciences USA 84, 881-885.
27. Kreek MJ, Nielsen DA, Butelman ER, LaForge KS (2005). Genetic influences on impulsivity, risk taking, stress responsivity and vulnerability to drug abuse and addiction. Nature Neuroscience 8, 1450-1457.
28. Linnoila M, Virkkunen M, Scheinin M, Nuutila A, Rimon R, Goodwin FK (1983). Low cerebrospinal fluid 5-hydroxyindoleacetic acid concentration differentiates impulsive from nonimpulsive violent behavior. Life Sciences 33, 2609-2614.
29. Machado-Vieira R, Lara DR, Portela LV, Goncalves CA, Soares JC, Kapczinski F, Souza DO (2002). Elevated serum S100B protein in drug-free bipolar patients during first manic episode: a pilot study. European Neuropsychopharmacology 12, 269-272.
30. Machado-Vieira R, Schmidt AP, Avila TT, Kapczinski F, Soares JC, Souza DO, Portela LV (2004). Increased cerebrospinal fluid levels of S100B protein in rat model of mania induced by ouabain. Life Sciences 76, 805-811.
31. Maldonado E, Navarro JF (2000). Effects of 3,4-methylenedioxy- methamphetamine (MDMA) on anxiety in mice tested in the light-dark box. Progress in Neuropsychopharmacology & Biological Psychiatry 24, 463-472.
32. Manev H, Manev R (2001). S100B: an old neurotrophic factor with putative new roles in psychiatric illnesses. Journal of Psychiatric Research 35, 347-350.
33. Maroteaux L, Saudou F, Amlaiky N, Boschert U, Plassat JL, Hen R (1992). Mouse 5HT1B serotonin receptor: cloning, functional expression, and localization in motor control centers. Proceedings of the National Academy of Sciences USA 89, 3020-3024.
34. McCreary AC, Bankson MG, Cunningham KA (1999). Pharmacological studies of the acute and chronic effects of (+)3, 4-methylenedioxymethamphetamine on locomotor activity: role of 5-hydroxytryptamine(1A) and 5-hydroxytryptamine(1B/ 1D) receptors. Journal of Pharmacology and Experimental Therapeutics 290, 965-973.
35. Mordenti J, Chappell W (1989). The use of interspecies scaling in toxicokinetics. In: Yacogi A, Kelley J, Batra V (Eds.), Toxicokinetics and New Drug Development (pp. 42-96). New York: Pergamon Press.
36. Morgan MJ (1998). Recreational use of 'ecstasy' (MDMA) is associated with elevated impulsivity. Neuro-psychopharmacology 19, 252-264.
37. Morton J (2005). Ecstasy: pharmacology and neurotoxicity. Current Opinion in Pharmacology 5, 79-86.
38. Nestler EJ (2005). Is there a common molecular pathway for addiction? Nature Neuroscience 8, 1445-1449.
39. Nestler EJ, Aghajanian GK (1997). Molecular and cellular basis of addiction. Science 278, 58-63.
40. Nishiyama H, Knopfel T, Endo S, Itohara S (2002). Glial protein S100B modulates long-term neuronal synaptic plasticity. Proceedings of the National Academy of Sciences USA 99, 4037-4042.
41. O'Shea E, Esteban B, Camarero J, Green AR, Colado MI (2001). Effect of GBR 12909 and fluoxetine on the acute and long term changes induced by MDMA ('ecstasy') on the 5-HT and dopamine concentrations in mouse brain. Neuropharmacology 40, 65-74.
42. Parrott AC (2002). Recreational Ecstasy/MDMA, the serotonin syndrome, and serotonergic neurotoxicity. Pharmacology Biochemistry & Behavior 71, 837-844.
43. Parrott AC (2005). Chronic tolerance to recreational MDMA (3,4-methylenedioxymethamphetamine) or Ecstasy. Journal of Psychopharmacology 19, 71-83.
44. Paxinos G, Watson C (1997). The Rat Brain in Stereotaxic Coordinates. San Diego: Academic Press Inc.
45. Pontieri FE, Tanda G, Di Chiara G (1995). Intravenous cocaine, morphine, and amphetamine preferentially increase extracellular dopamine in the 'shell' as compared with the 'core' of the rat nucleus accumbens. Proceedings of the National Academy of Sciences USA 92, 12304-12308.
46. Powell SB, Lehmann-Masten VD, Paulus MP, Gainetdinov RR, Caron MG, Geyer MA (2004). MDMA 'ecstasy' alters hyperactive and perseverative behaviors in dopamine transporter knockout mice. Psychopharmacology (Berlin) 173, 310-317.
47. Reeves RH, Yao J, Crowley MR, Buck S, Zhang X, Yarowsky P, Gearhart JD, Hilt DC (1994). Astrocytosis and axonal proliferation in the hippocampus of S100b transgenic mice. Proceedings of the National Academy of Sciences USA 91, 5359-5363.
48. Rempel NL, Callaway CW, Geyer MA (1993). Serotonin1B receptor activation mimics behavioral effects of presynaptic serotonin release. Neuropsychopharmacology 8, 201-211.
49. Risbrough VB, Masten VL, Caldwell S, Paulus MP, Low MJ, Geyer MA (2006). Differential contributions of dopamine D1, D2, and D3 receptors to MDMA-induced effects on locomotor behavior patterns in mice. Neuropsychopharmacology 31, 2349-2358.
50. Roche S, Cassidy F, Zhao C, Badger J, Claffey E, Mooney L, Delaney C, Dobrin S, McKeon P (2007). Candidate gene analysis of 21q22: support for S100B as a susceptibility gene for bipolar affective disorder with psychosis. American Journal of Medical Genetics, Part B: Neuropsychiatric Genetics 144B, 1094-1096.
51. Rothermundt M, Missler U, Arolt V, Peters M, Leadbeater J, Wiesmann M, Rudolf S, Wandinger KP, Kirchner H (2001). Increased S100B blood levels in unmedicated and treated schizophrenic patients are correlated with negative symptomatology. Molecular Psychiatry 6, 445-449.
52. Rothermundt M, Peters M, Prehn JH, Arolt V (2003). S100B in brain damage and neurodegeneration. Microscopy Research and Technique 60, 614-632.
53. Rothermundt M, Ponath G, Arolt V (2004). S100B in schizophrenic psychosis. International Review of Neurobiology 59, 445-470.
54. Rothman RB, Baumann MH (2003). Monoamine transporters and psychostimulant drugs. European Journal of Pharmacology 479, 23-40.
55. Sari Y, Miquel MC, Brisorgueil MJ, Ruiz G, Doucet E, Hamon M, Verge D (1999). Cellular and subcellular localization of 5-hydroxytryptamine1B receptors in the rat central nervous system: immunocytochemical, autoradiographic and lesion studies. Neuroscience 88, 899-915.
56. Scearce-Levie K, Viswanathan SS, Hen R (1999). Locomotor response to MDMA is attenuated in knockout mice lacking the 5-HT1B receptor. Psychopharmacology (Berlin) 141, 154-161.
57. Schultz W (1998). Predictive reward signal of dopamine neurons. Journal of Neurophysiology 80, 1-27.
58. Spanagel R, Weiss F (1999). The dopamine hypothesis of reward: past and current status. Trends in Neuroscience 22, 521-527.
59. Svenningsson P, Chergui K, Rachleff I, Flajolet M, Zhang X, El Yacoubi M, Vaugeois JM, Nomikos GG, Greengard P (2006). Alterations in 5-HT1B receptor function by p11 in depression-like states. Science 311, 77-80.
60. Svenningsson P, Le Moine C, Kull B, Sunahara R, Bloch B, Fredholm BB (1997). Cellular expression of adenosine A2A receptor messenger RNA in the rat central nervous system with special reference to dopamine innervated areas. Neuroscience 80, 1171-1185.
61. Svenningsson P, Nomikos GG, Fredholm BB (1995). Biphasic changes in locomotor behavior and in expression of mRNA for NGFI-A and NGFI-B in rat striatum following acute caffeine administration. Journal of Neuroscience 15, 7612-7624.
62. Winstanley CA, Dalley JW, Theobald DE, Robbins TW (2004). Fractionating impulsivity: contrasting effects of central 5-HT depletion on different measures of impulsive behavior. Neuropsychopharmacology 29, 1331-1343.
63. Yoshikawa K, Williams C, Sabol SL (1984). Rat brain preproenkephalin mRNA. cDNA cloning, primary structure, and distribution in the central nervous system. Journal of Biological Chemistry 259, 14301-14308.